Gland Pharma Q1FY27 Results: Revenue up 20% to ₹18,003 Cr, PAT grows 47%
Gland Pharma reported Q1FY27 revenue of ₹18,003 crore, up 20% YoY. PAT grew 47% to ₹3,170 crore. CDMO revenue increased 20% and B2B revenue rose 19%. The company launched 4 molecules in the USA and filed 3 ANDAs. Strategic collaborations and in-licensing agreements were also highlighted.
The substantial year-on-year growth in revenue and profit, coupled with strategic business updates and product launches, indicates a significant positive impact on the company's performance and future outlook.
The company reported significant year-on-year growth in revenue and profit, along with positive business updates and strategic developments.
Gland Pharma Limited has released its investor presentation for the first quarter of fiscal year 2027 (Q1FY27), detailing robust financial performance.
For the quarter ended June 30, 2026, the company reported a consolidated revenue from operations of ₹18,003 crore, marking a significant 20% year-on-year increase from ₹15,056 crore in Q1FY26. This growth was driven by a 20% rise in CDMO revenue to ₹8,915 crore and a 19% increase in B2B revenue to ₹9,088 crore.
Gross Profit saw a 19% rise to ₹11,759 crore, with the Gross Profit margin remaining stable at 65%. EBITDA grew by 34% to ₹4,930 crore, and Adjusted EBITDA increased by 37% to ₹5,102 crore. The company's Profit Before Tax (PBT) surged by 39% to ₹4,350 crore, and Profit After Tax (PAT) saw a substantial 47% jump to ₹3,170 crore. Consequently, the PAT margin improved to 18% from 14% in the same period last year.
Key business updates include the launch of 4 molecules in the USA, with R&D expenses standing at ₹772 million (4% of consolidated revenue). The company filed three ANDAs and received seven approvals in Q1FY27, bringing the cumulative US filings to 389. Gland Pharma also highlighted its in-house complex pipeline, co-development partnerships, and the significant market opportunity for its Ready-to-Use (RTU) bags in the US, estimated at $644 million. Additionally, strategic collaborations with Neuland Laboratories and an in-licensing agreement with a China-based company for a niche liposomal product were mentioned.
Geographically, the US market contributed 54% to revenue, with CDMO and B2B segments showing growth. Europe reported a 20% year-on-year increase in both B2B and CDMO revenues. Other core markets experienced a decline, while Rest of the World (RoW) saw a 2% YoY growth in CDMO and a 6% YoY growth in B2B. India's CDMO segment grew by 56% YoY, though B2B declined by 36% YoY due to lower sales of Enoxaparin.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.